111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) saw a large decline in short interest in October. As of October 15th, there was short interest totaling 4,313 shares, a decline of 38.5% from the September 30th total of 7,014 shares. Based on an average daily trading volume, of 12,201 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the shares of the stock are short sold.
Analysts Set New Price Targets
Separately, Weiss Ratings cut shares of 111 from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 13th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, 111 has a consensus rating of “Sell”.
Read Our Latest Analysis on 111
111 Stock Up 3.3%
NASDAQ:YI traded up $0.10 during trading hours on Monday, reaching $2.94. The company had a trading volume of 1,653 shares, compared to its average volume of 26,124. The firm has a market capitalization of $25.87 million, a PE ratio of -1.84 and a beta of 0.67. 111 has a one year low of $2.48 and a one year high of $11.17. The stock has a 50-day moving average of $3.33 and a two-hundred day moving average of $5.05.
111 (NASDAQ:YI – Get Free Report) last released its quarterly earnings results on Friday, September 18th. The company reported ($0.60) EPS for the quarter. The company had revenue of $338.55 million during the quarter.
About 111
111, Inc is a China-based healthcare technology company that operates an online platform connecting consumers, pharmaceutical manufacturers, distributors and healthcare providers. The company focuses on improving access to medicines and health-related products through digital retail and supply-chain services.
Its business includes online sales of prescription and over-the-counter medicines, nutritional products, medical devices and other healthcare products. Through its technology platform, 111 also provides services intended to support pharmaceutical companies and pharmacies with product distribution, marketing, data and fulfillment.
Founded in 2010 and headquartered in Shanghai, 111 serves customers and healthcare businesses in China.
See Also
- Five stocks we like better than 111
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
